Search

Respimat re-usable wins Pharmapack Eco-Design Award

The Respimat® re-usable inhaler device has won the 2020 Pharmapack Eco-Design Award. An enhanced version of the Respimat® soft mist inhaler, Respimat® re-usable has a lower environmental impact and is easy for patients to use.

empa-reg-outcome-recurrent-events

EMPA-REG OUTCOME® analysis: Empagliflozin reduced risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and CV disease

Brazil boosts biosecurity in dairy farms

We partnered with Embrapa to help farmers and local authorities set best practices in biosecurity for dairy through a biosecurity certificate.

Immunology

Human Pharma Clinical Pipeline Immunology therapeutic area

Access to Healthcare: How we help underserved communities

Access to healthcare is not a given for everyone. We are partnering with an organization in Rome to help underserved communities.

Acquisition expands research in cancer immunology

Boehringer Ingelheim acquires Abexxa to develop novel cancer therapies by leveraging Abexxa’s unique technology and breakthrough antibody-based drugs.

EU approved Jardiance for type 2 diabetes in children

Jardiance® (empagliflozin) receives approval in the EU for the treatment of type 2 diabetes in children aged 10 years and above

Labor & Human Rights

Suppliers shall support and respect the protection of internationally proclaimed human rights.

Giving Life a Chance

The Angels initiative honours stroke units and the everyday heroes making a difference for stroke patients

Pioneering for progress in generalized pustular psoriasis

An event, bringing together 170 delegates from across the world to strive for excellence in care of GPP

Second cancer immunotherapy partnership with 3T Bio

PRRS Research Award 2022

Bridging science and veterinary practice for swine health: The winners of the European PRRS Award 2022

New cancer therapeutics collaboration with 3T Bio

Boehringer Ingelheim and 3T Biosciences collaborate to discover and develop next-generation cancer therapies to address high unmet patient needs

Partnership with Precision Health Research, Singapore

Boehringer Ingelheim joins forces with Precision Health Research, Singapore with the aim of transforming healthcare and improving patient outcomes in Singapore and beyond.

Celebrating 20 years of Metacam for cattle

Celebrating 20 years of Metacam (Meloxicam) for cattle

The first liquid solution for hypertension in cats

Boehringer Ingelheim launches Semintra® 10 mg/ml Oral Solution in selected European countries for the treatment of feline hypertension.

Launch of BVDzero scholarship for veterinary students

Launch of BVDzero scholarship for veterinary students globally

Phase II trial results in people living with obesity or overweight

Phase II trial with BI 456906 met primary endpoint after 46 weeks of treatment, representing an important advancement of Boehringer Ingelheim’s cardio-renal-metabolic focus areas

Tackling NCDs through innovation AND collaboration

Non-communicable diseases are a significant medical, humanitarian and socio-economic issue. Rapid innovation and holistic approaches help us tackle them

Uncommon_Mutations_Database

New database of published clinical outcomes from patients with uncommon EGFR mutations in advanced NSCLC treated with afatinib is available for global clinician use

License deal with A*STAR to develop cancer antibodies

New Partnership to Develop Gene Therapy for Cystic Fibrosis

Boehringer Ingelheim steps into the field of gene therapy with experienced partners to jointly develop first gene therapy for cystic fibrosis

Results for Jardiance EMPACT-MI phase III trial

Results announced from EMPACT-MI phase III trial investigating the effect of Jardiance® (empagliflozin) on risk of heart failure hospitalization and death in adults following a heart attack

Biosecurity in farms: what’s this all about

Biosecurity is one of the three pillars we focus on: vaccination, biosecurity, and surveillance. But what is biosecurity in farms?

Neovascular AMD (wet AMD)

Neovascular AMD (or wet AMD) is a severe form of advanced age-related macular degeneration that can lead to irreversible vision loss if untreated

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers